Background A previously healthy 47-year-old woman presented reporting nausea, anorexia and light-headedness of 2 weeks' duration, and three episodes of syncope. She also had pleuritic chest pain and ...

PONTE VEDRA, Fla., April 9, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant ...

Total Artificial Heart Manufacturer Only Company to Make the List with an FDA-Approved Mechanical Circulatory Support Device TUCSON, Ariz.--(BUSINESS WIRE)-- Medical Device and Diagnostic Industry ...

"Cardiac Assist Devices Market Insights, Competitive Landscape, and Market Forecast - 2030"The Cardiac Assist Devices market, valued at $3B in 2023, is set to reach $6.23B by 2030 at a CAGR of 13.7%.

Research and Markets has announced the addition of the "Ventricular Assistance Devices Global Market - Forecast to 2023" report to their offering. The heart conditions are considered advanced or end ...

NEW ORLEANS, Nov. 9 - A heart ventricular assist device (VAD) is used as a bridge to organ transplantation, maintaining a patient's cardiac function until a donor organ becomes available. In some ...

DUBLIN--(BUSINESS WIRE)--The "North America Ventricular Assist Devices (VADs) Market (2018 - 2024)" report has been added to ResearchAndMarkets.com's offering. Ventricular assist devices are ...

The "Global Cardiac Assist Devices (CAD) Market - Forecasts to 2024" report has been added to ResearchAndMarkets.com's offering. Cardiac assist devices global market is expected to grow at a double ...

For the first time at Children's Hospital of Philadelphia (CHOP), a team successfully performed a total artificial heart surgery on an infant with complex congenital heart disease supported by a ...

DUBLIN--(BUSINESS WIRE)--The "Ventricular Assist Devices Market by Product, Application, and Design - Global Opportunity Analysis and Industry Forecast, 2017-2023" report has been added to ...

FDA designation provides potentially seven years of market exclusivity after approval and expanded partnering opportunities for tecarfarin PONTE VEDRA, Fla., April 9, 2024 /PRNewswire/ -- Cadrenal ...